Guardant Health, Inc. ( GH ) is a cancer genomics diagnostics company. GH leverages the SMART platform, which spans screening, therapy selection, minimal residual disease (MRD), and surveillance across all stages of cancer. GH’s business segments include Oncology as the anchor, Screening, and Biopharma & Data. InMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science f ...

We recently published 10 Stocks with Outstanding Gains; 9 on Record Highs. Guardant Health Inc. (NASDAQ:GH) is one of the best-performing stocks on Thursday. Guardant Health soared to a fresh record high on Thursday, as investors took heart from an impressive earnings performance and a higher growth outlook for the full-year period. During the trading session, Guardant Health Inc. (NASDAQ:GH) jumped to its highest level of $95.88 before paring gains to end the day just up by 27.87 percent at $92.41 apiec ...

Key Points The cancer-focused biotech surprised on the upside for both revenue and profitability in its latest reported quarter. Revenue rose by almost 40% year over year in that period. 10 stocks we like better than Guardant Health › Guardant Health (NASDAQ: GH) unveiled its latest set of quarterly results on Thursday, and the biotech's encouraging performance gave the stock significant upward momentum. The company's shares were up by 28% week to date as of early Friday morning, according to data c ...

Richard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can be achieved by identifying businesses with secular growth opportunities in markets with barriers to entry. Narweena’s research process is focused on company and industry fundamentals with the goal of uncovering unique insights. Narweena has a high risk appetite and a long-term ...

Richard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can be achieved by identifying businesses with secular growth opportunities in markets with barriers to entry. Narweena’s research process is focused on company and industry fundamentals with the goal of uncovering unique insights. Narweena has a high risk appetite and a long-term ...

Key Points Guardant's oncology and screening businesses are expanding at a rapid pace. New partnerships should drive further gains. 10 stocks we like better than Guardant Health › Shares of Guardant Health (NASDAQ: GH) rocketed 28% higher on Thursday after the precision oncology company reported outstanding growth metrics across its key product lines. Image source: Getty Images. Doing well by doing good Guardant's third-quarter revenue soared by 39% year over year to $265.2 million. The gains we ...

TRENDING: You Don't Have To Dig Far To Cash In On Rare EarthsGuardant Health (GH) stock rocketed Thursday on an impressive beat-and-raise earnings report that included 40% volume growth from its oncology division.That 40% volume growth for oncology tests was a "wow," William Blair analyst Andrew Brackmann said in a report. The company's suite of liquid biopsy tests, including Guardant360, use genomic profiling to determine the drivers of a patient's cancer. This helps doctors select the right, targeted trea ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Shares of Guardant Health Inc. (GH) are up over 25% at $90 in premarket trading on Thursday, after the company reported exceptionally strong financial results for the quarter ended September 30, 2025, and raised its full-year 2025 outlook.This commercial-stage precision oncology company Guardant360 Liquid test and Guardant360 CDx test, the first comprehensive liquid biopsy test approved by the FDA to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection w ...

Core Viewpoint - The article discusses the importance of enabling Javascript and cookies in browsers to ensure proper functionality and access to content [1] Group 1 - The article highlights that users may face access issues if they have an ad-blocker enabled [1] - It suggests disabling ad-blockers and refreshing the page to proceed [1]